Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash & Equivalents (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Cash & Equivalents data on record, last reported at $134.9 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 12.43% year-over-year to $134.9 million; the TTM value through Dec 2025 reached $134.9 million, down 12.43%, while the annual FY2025 figure was $134.9 million, 12.43% down from the prior year.
  • Cash & Equivalents reached $134.9 million in Q4 2025 per SNDX's latest filing, up from $116.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $295.4 million in Q4 2023 and bottomed at $57.5 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $122.4 million, with a median of $111.6 million recorded in 2024.
  • The widest YoY moves for Cash & Equivalents: up 297.27% in 2023, down 69.53% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $222.1 million in 2021, then plummeted by 66.52% to $74.4 million in 2022, then skyrocketed by 297.27% to $295.4 million in 2023, then plummeted by 47.84% to $154.1 million in 2024, then decreased by 12.43% to $134.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $134.9 million in Q4 2025, $116.8 million in Q3 2025, and $108.6 million in Q2 2025.